367 related articles for article (PubMed ID: 22471524)
41. Effects of antipsychotic medication on psychiatric service utilization and cost.
Rothbard A; Murrin MR; Jordan N; Kuno E; McFarland BH; Stroup TS; Morrissey JP; Stiles PG; Boothroyd RA; Merwin E; Shern DL
J Ment Health Policy Econ; 2005 Jun; 8(2):83-93. PubMed ID: 15998980
[TBL] [Abstract][Full Text] [Related]
42. How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs.
Valuck RJ; Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R;
Curr Med Res Opin; 2007 Oct; 23(10):2567-76. PubMed ID: 17848204
[TBL] [Abstract][Full Text] [Related]
43. Cost of care for Medicaid recipients with serious mental illness and HIV infection or AIDS.
Rothbard AB; Metraux S; Blank MB
Psychiatr Serv; 2003 Sep; 54(9):1240-6. PubMed ID: 12954940
[TBL] [Abstract][Full Text] [Related]
44. High-Expenditure Pharmaceutical Use Among Children in Medicaid.
Cohen E; Hall M; Lopert R; Bruen B; Chamberlain LJ; Bardach N; Gedney J; Zima BT; Berry JG
Pediatrics; 2017 Sep; 140(3):. PubMed ID: 28765380
[TBL] [Abstract][Full Text] [Related]
45. Psychotropic Medication Prescribing: Youth in Foster Care Compared with Other Medicaid Enrollees.
Keefe RJ; Cummings ADL; Smith AE; Greeley CS; Van Horne BS
J Child Adolesc Psychopharmacol; 2023 May; 33(4):149-155. PubMed ID: 37204275
[No Abstract] [Full Text] [Related]
46. Psychotropic medication use among Kansas Medicaid youths with disabilities.
Shireman TI; Reichard A; Rigler SK
J Child Adolesc Psychopharmacol; 2005 Feb; 15(1):107-15. PubMed ID: 15741792
[TBL] [Abstract][Full Text] [Related]
47. Autism Prevalence in the Medicaid Program and Healthcare Utilization and Costs Among Adult Enrollees Diagnosed with Autism.
Jariwala-Parikh K; Barnard M; Holmes ER; West-Strum D; Bentley JP; Banahan B; Khanna R
Adm Policy Ment Health; 2019 Nov; 46(6):768-776. PubMed ID: 31352637
[TBL] [Abstract][Full Text] [Related]
48. Frequency of purchase and associated costs of assistive technology for Washington State Medicaid program enrollees with spina bifida by age.
Bamer AM; Connell FA; Dudgeon BJ; Johnson KL
Disabil Health J; 2010 Jul; 3(3):155-61. PubMed ID: 21122780
[TBL] [Abstract][Full Text] [Related]
49. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs.
Svarstad BL; Shireman TI; Sweeney JK
Psychiatr Serv; 2001 Jun; 52(6):805-11. PubMed ID: 11376229
[TBL] [Abstract][Full Text] [Related]
50. Prescription Trends of Psychotropics in Children and Adolescents with Autism Based on Nationwide Health Insurance Data.
Hong M; Lee SY; Han J; Park JC; Lee YJ; Hwangbo R; Chang H; Cho SW; Bhang SY; Kim B; Hwang JW; Bahn GH
J Korean Med Sci; 2017 Oct; 32(10):1687-1693. PubMed ID: 28875615
[TBL] [Abstract][Full Text] [Related]
51. Medication use and spending trends among children with ADHD in Florida's Medicaid program, 1996-2005.
Fullerton CA; Epstein AM; Frank RG; Normand SL; Fu CX; McGuire TG
Psychiatr Serv; 2012 Feb; 63(2):115-21. PubMed ID: 22302327
[TBL] [Abstract][Full Text] [Related]
52. Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths.
Zito JM; Safer DJ; Zuckerman IH; Gardner JF; Soeken K
Psychiatr Serv; 2005 Feb; 56(2):157-63. PubMed ID: 15703342
[TBL] [Abstract][Full Text] [Related]
53. Characterization of Chronic Multiclass Psychotropic Polypharmacy and Psychotherapy in Foster Care Youth in a State Medicaid Population.
Keast SL; Tidmore LM; Shropshire D; Nesser N; Lambert TL
J Manag Care Spec Pharm; 2019 Dec; 25(12):1340-1348. PubMed ID: 31778625
[TBL] [Abstract][Full Text] [Related]
54. Multiple psychotropic medication use for youths: a two-state comparison.
dosReis S; Zito JM; Safer DJ; Gardner JF; Puccia KB; Owens PL
J Child Adolesc Psychopharmacol; 2005 Feb; 15(1):68-77. PubMed ID: 15741788
[TBL] [Abstract][Full Text] [Related]
55. Childhood adversities predict strongly the use of psychotropic drugs in adulthood: a population-based cohort study of 24,284 Finns.
Koskenvuo K; Koskenvuo M
J Epidemiol Community Health; 2015 Apr; 69(4):354-60. PubMed ID: 25538256
[TBL] [Abstract][Full Text] [Related]
56. Utilization of psychotropic drugs in Taiwan: an overview of outpatient sector in 2000.
Su TP; Chen TJ; Hwang SJ; Chou LF; Fan AP; Chen YC
Zhonghua Yi Xue Za Zhi (Taipei); 2002 Aug; 65(8):378-91. PubMed ID: 12455808
[TBL] [Abstract][Full Text] [Related]
57. Factors associated with psychotropic prescriptions, psychiatric hospitalization, and spending among Medicare beneficiaries under 65.
Qian J; Wittayanukorn S; McGuffey G; Hansen R
Disabil Health J; 2015 Jul; 8(3):424-33. PubMed ID: 25890881
[TBL] [Abstract][Full Text] [Related]
58. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina.
Langworthy-Lam KS; Aman MG; Van Bourgondien ME
J Child Adolesc Psychopharmacol; 2002; 12(4):311-21. PubMed ID: 12625991
[TBL] [Abstract][Full Text] [Related]
59. Medication use among children with autism spectrum disorders.
Oswald DP; Sonenklar NA
J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):348-55. PubMed ID: 17630868
[TBL] [Abstract][Full Text] [Related]
60. Changes in drug coverage generosity and untreated serious mental illness: transitioning from Medicaid to Medicare Part D.
Madden JM; Adams AS; LeCates RF; Ross-Degnan D; Zhang F; Huskamp HA; Gilden DM; Soumerai SB
JAMA Psychiatry; 2015 Feb; 72(2):179-88. PubMed ID: 25588123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
